| Christopher H Mai, MD | |
|
98-1079 Moanalua Rd, Ste 480, Aiea, HI 96701-4713 | |
| (808) 487-9667 | |
| (808) 487-1484 |
| Full Name | Christopher H Mai |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 35 Years |
| Location | 98-1079 Moanalua Rd, Aiea, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083728844 | NPI | - | NPPES |
| D53290 | Other | HI | HMSA |
| 04688101 | Medicaid | HI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | MD7152 (Hawaii) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Island Eye Center Inc | 1951486059 | 2 |
News Archive
The American Academy of Child and Adolescent Psychiatry (AACAP) is pleased to announce David A. Axelson, M.D, Assistant Professor of Psychiatry, University of Pittsburgh School of Medicine, and Western Psychiatric Institute and Clinic, and Director, Child and Adolescent Bipolar Services, Western Psychiatric Institute and Clinic, as the recipient of the Klingenstein Third Generation Foundation Award for Research in Depression or Suicide for his paper, "Course of Subthreshold Bipolar Disorder in Youth: Diagnostic Progression From Bipolar Disorder Not Otherwise Specified," published in the October 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.
The National Council on Disability (NCD) will hear presentations and discuss employment, health care, and restraint and seclusion issues affecting people with disabilities during its quarterly meeting at the Holiday Inn Express, 920 Broadway, Nashville, TN, which begins at 8:30 a.m. on Monday, October 26, 2009, and concludes at 11:00 a.m. on Wednesday, October 28, 2009.
The Parkinson's Institute today announced that new findings concerning the role of environmental factors in the development of Parkinson's disease will be reported at Asilomar (Pacific Grove, CA) as part of the final meeting of the Collaborative Centers for Parkinson's Disease Environmental Research (CCPDER).
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
› Verified 7 days ago
| Entity Name | Island Eye Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497869242 PECOS PAC ID: 1951486059 Enrollment ID: O20080313000506 |
News Archive
The American Academy of Child and Adolescent Psychiatry (AACAP) is pleased to announce David A. Axelson, M.D, Assistant Professor of Psychiatry, University of Pittsburgh School of Medicine, and Western Psychiatric Institute and Clinic, and Director, Child and Adolescent Bipolar Services, Western Psychiatric Institute and Clinic, as the recipient of the Klingenstein Third Generation Foundation Award for Research in Depression or Suicide for his paper, "Course of Subthreshold Bipolar Disorder in Youth: Diagnostic Progression From Bipolar Disorder Not Otherwise Specified," published in the October 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.
The National Council on Disability (NCD) will hear presentations and discuss employment, health care, and restraint and seclusion issues affecting people with disabilities during its quarterly meeting at the Holiday Inn Express, 920 Broadway, Nashville, TN, which begins at 8:30 a.m. on Monday, October 26, 2009, and concludes at 11:00 a.m. on Wednesday, October 28, 2009.
The Parkinson's Institute today announced that new findings concerning the role of environmental factors in the development of Parkinson's disease will be reported at Asilomar (Pacific Grove, CA) as part of the final meeting of the Collaborative Centers for Parkinson's Disease Environmental Research (CCPDER).
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher H Mai, MD 98-1079 Moanalua Rd, Ste 480, Aiea, HI 96701-4713 Ph: (808) 487-9667 | Christopher H Mai, MD 98-1079 Moanalua Rd, Ste 480, Aiea, HI 96701-4713 Ph: (808) 487-9667 |
News Archive
The American Academy of Child and Adolescent Psychiatry (AACAP) is pleased to announce David A. Axelson, M.D, Assistant Professor of Psychiatry, University of Pittsburgh School of Medicine, and Western Psychiatric Institute and Clinic, and Director, Child and Adolescent Bipolar Services, Western Psychiatric Institute and Clinic, as the recipient of the Klingenstein Third Generation Foundation Award for Research in Depression or Suicide for his paper, "Course of Subthreshold Bipolar Disorder in Youth: Diagnostic Progression From Bipolar Disorder Not Otherwise Specified," published in the October 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.
The National Council on Disability (NCD) will hear presentations and discuss employment, health care, and restraint and seclusion issues affecting people with disabilities during its quarterly meeting at the Holiday Inn Express, 920 Broadway, Nashville, TN, which begins at 8:30 a.m. on Monday, October 26, 2009, and concludes at 11:00 a.m. on Wednesday, October 28, 2009.
The Parkinson's Institute today announced that new findings concerning the role of environmental factors in the development of Parkinson's disease will be reported at Asilomar (Pacific Grove, CA) as part of the final meeting of the Collaborative Centers for Parkinson's Disease Environmental Research (CCPDER).
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
› Verified 7 days ago
Dr. Kenneth C.m. Lee, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 98-151 Pali Momi St, Suite 142, Aiea, HI 96701 Phone: 808-483-6400 Fax: 808-483-6489 | |
Dr. Raymond Wee, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 98-1079 Moanalua Road, Suite 470, Aiea, HI 96701 Phone: 808-487-8928 Fax: 808-487-3699 | |
Dr. Sarah Parker Read, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 98-1079 Moanalua Rd Ste 470, Aiea, HI 96701 Phone: 808-487-8928 | |
William K Wong Jr., M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 99-128 Aiea Heights Dr, Suite 703, Aiea, HI 96701 Phone: 808-487-7938 Fax: 808-485-8022 | |
Prof. Geoffrey V. Davis, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 98-211 Pali Momi St, Suite 820, Aiea, HI 96701 Phone: 808-487-8993 Fax: 808-486-9409 | |
Gregg T Kokame, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 98-1079 Moanalua Road, #470, Aiea, HI 96701 Phone: 808-487-8928 Fax: 808-487-3699 |